The facts – HOPE-NMP

  • HOPE-NMP is the first randomized controlled trial world-wide to investigate the effects of end-ischemic HOPE and end-ischemic NMP compared to CCS in a multi-center prospective randomized controlled clinical trial (RCT) using ECD liver grafts in DBD liver-transplantation (NCT04644744).
  • HOPE-NMP focuses on patients solely receiving ECD-allografts, a population we anticipate the best cost/benefit ratio from the utilization of HOPE.
  • HOPE-NMP focuses on donation after brain death, the most frequent source of ECD-allografts in Europe.
  • Multi-center design, currently 4 centers (Charité Universitätsmedizin Berlin, University Hospital Hannover, University Hospital Heidelberg, University Hospital Bonn)
  • Principal Investigator (Charité Universitätsmedizin Berlin): Georg Lurje, M.D.
  • Co-Principal Investigator (Charité Universitätsmedizin Berlin): Johann Pratschke, M.D.
  • Local Investigator (University Hospital Heidelberg): Arianeb Mehrabi, M.D.
  • Local Investigator (University Hospital Hannover): Florian Vondran, M.D.
  • Local Investigator (University Hospital Bonn): Steffen Manekeller, M.D., Tim Glowka, M.D., Martin von Websky, M.D.